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Abstract 
Non-steroidal anti-inflammatory drugs are commonly used in implant dentistry for management of 
post-operative pain. The objective of this systematic review was to analyse the effect of non-
steroidal anti-inflammatory drugs on the osteogenic activity of osteoblasts with an emphasis on its 
effect on osseointegration. A systematic literature search for in-vitro, animal models, and clinical 
trials was conducted using Ovid, PubMed, Scopus and Web of Science databases. Articles published 
since the introduction of selective COX-2 inhibitors, between January 1999 and May 2018, were 
selected. The integrated search followed the PRISMA statement with the following key terms; non-
steroidal anti-inflammatory drug/s, titanium, osseointegration, osteoblast. The review is registered 
at PROSPERO database: CRD42016051448. The titles and abstracts of each research article in the 
initial search (n=875) were independently screened by two reviewers. A third independent reviewer 
reviewed the articles that were included by one but excluded by the other reviewer. This resulted in 
the cataloguing of 79 full-text manuscripts where the articles were assessed for the following 
criteria: the study investigates the effects of NSAIDs on osteoblasts, explored the COX pathway and 
its effect on osteogenic activity, and compares the effects of NSAIDs on osteoblasts with a control 
group. A total of 13 articles have been included for qualitative synthesis. There is a lack of consensus 
in the literature to explicitly conclude that there is a relationship between the use of post-operative 
NSAIDs and failed osseointegration, however, osseointegration does not appear to be negatively 
affected by NSAIDs in the human clinical studies. 
Introduction 
Non-steroidal anti-inflammatory drugs (NSAIDs) are a group of drugs with anti-inflammatory, 
analgesic, and antipyretic effects. They are commonly used in dentistry for management of dental 
pain associated with inflammation. NSAIDs exert their effects through the inhibition of the 
cyclooxygenase (COX) enzyme, and therefore interfering with the synthesis of prostaglandins (PG) 
and thromboxanes; PGs and thromboxanes are inflammatory mediators that are responsible for 
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pain. COX has three isoforms: COX-1, COX-2, and COX-3. COX-1 exhibits characteristics of a 
constitutive enzyme, as its activity is associated with the involvement of PGs and thromboxanes in 
controlling normal physiological functions {Salari, 2009 #193}. COX-2 exhibits characteristics of an 
inducible enzyme in inflammatory cells and is activated in response to pathological stimuli 
{Boursinos, 2009 #371}. COX-3 is a variant of COX-1, though it shares the characteristics of both COX-
1 and COX-2. The osseointegration process that is observed after implant insertion can be compared 
to bone fracture healing through the process of an inflammatory response in which the recruitment 
of osteoprogenitor cells occurs, followed by their down-stream differentiation into osteoblasts that 
leads to bone deposition on the implant surface {Kalyvas, 2008 #417;Gomes, 2015 #7}. COX-1 is 
expressed in normal bone and at the site of bone fracture, while COX-2 is up-regulated during 
inflammation and the initial stages of bone repair {Pountos, 2012 #313}. The effects of NSAIDs on 
altering bone growth, remodelling and repair are generally not considered when prescribed for post-
operative pain management after implant placement.  
Hypoxia occurs locally in bone tissues when pathological conditions such as implant placement and 
bone fractures arise {van Esch, 2013 #949;Fracon, 2008 #209}. It has been established, through 
clinical studies of bone cultures, that hypoxia is directly responsible for directing the synthesis of 
prostaglandin E (PGE) by osteoblasts {van Esch, 2013 #949}. Therefore, the presence of the COX 
enzymes in bone healing is of importance {van Esch, 2013 #949}. Prostaglandins have the capacity to 
influence bone metabolism and can both induce and inhibit tissue repair mechanisms {van Esch, 
2013 #949}. Local administration of PGE1 has been shown to stimulate bone formation, increase 
alveolar bone height, and induce formation of new cementum and periodontal ligament adjacent to 
the site of delivery in canine mandibles {Marks, 1994 #2171;Trombelli, 1999 #2170}. Furthermore, 
PGE2 has been shown to stimulate replication and differentiation of osteoblasts cultured on smooth 
titanium surfaces thereby increasing bone formation around titanium implants {Dean, 2008 #72}. 
Additionally, PGs can also inhibit the formation and growth of osteoblasts {van Esch, 2013 #949}. 
Therefore, altered PG levels as a result of COX inhibition can have a negative impact on the role of 
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PG in bone tissue, potentially causing a shift in precursor cell action towards bone resorption {van 
Esch, 2013 #949}.  
Cyclooxygenases have an important role in the production of PGs where these enzymes in bone 
tissues show increased activity under the influence of hypoxia-inducible factors {van Esch, 2013 
#949;Geusens, 2013 #960}. Therefore, local activity of COX enzymes promotes bone formation and 
resorption through the production of PGs {Evans, 2004 #107}. Non-selective NSAIDs are reported to 
inhibit the activity of COX-1 equally, if not more than COX-2 {Boursinos, 2009 #371}. Therefore, 
NSAIDs inhibit the production of PGs at the site of implant placement or fracture and thereby 
influence the bone healing cascade {Müller, 2011 #1192}. There is evidence from animal studies that 
indicate that COX-2 inhibitors delay done healing in diaphyseal fracture models in rats {Müller, 2011 
#1192}. However, the exact roles of COX-1 and COX-2 in PG production has not been ascertained in 
humans and assumptions have been made suggesting a milder or non-significant inhibitory effect of 
selective COX-2 inhibitors on bone healing when compared to a non-selective COX inhibitor {Müller, 
2011 #1192;Boursinos, 2009 #371}. Furthermore, a systematic review conducted by Marquez-Lara et 
al. highlighted the great variability regarding the impact of NSAIDs on bone healing, and that there is 
no consensus regarding the impact of NSAIDs following orthopaedic procedures {Marquez-Lara, 
2016 #686}. Therefore, the rationale of the present systematic review is to address the gaps in the 
literature by identifying if variables such as the dosage, duration of administration, and selectivity of 
post-operative NSAIDs negatively affect osseointegration.  
Material and Methods 
Protocol and Registration 
The systematic review was conducted in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) statement {Liberati, 2009 #503}. The review is 
registered at PROSPERO database and the review protocol can be accessed at: 
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http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42016051448. 
The PROSPERO registration number: CRD42016051448. 
Eligibility Criteria 
The review included in-vitro, clinical and in-vivo studies; animal models. Articles published since the 
introduction of selective COX-2 inhibitors in 1999 were included {Kalyvas, 2008 #417}. Studies 
published outside this time-period, not in the English language, non-peer reviewed, and review 
studies were excluded.  
Information Sources 
An electronic search into four databases: Ovid, Pubmed, Scopus and Web of Science was performed 
to systematically identify the available literature. Articles published between January 1st, 1999 and 
July 7th, 2018 were considered. 
Focus Question 
The focus question, used to guide the search strategy, according to the PICO schema is: “Will 
variables such as the dosage, duration of administration, and selectivity of post-operative NSAIDs 
impair the bone-healing around titanium implants?”. 
Search Strategy 
The search string comprised the combination of medical subject headings (MeSH) and free 
keywords. The linkage was conducted using the Boolean operator (AND, OR). The choice of 
keywords was intended to be broad to maximise the number of relevant studies considered. The 
following search strategy was applied to Ovid and PubMed: 
1) (anti inflammatory agents, non steroidal[MeSH Terms]) AND osseointegration[MeSH Terms] 
2) (anti inflammatory agents, non steroidal[MeSH Terms]) AND osteoblast[MeSH Terms] 
3) (anti inflammatory agents, non steroidal[MeSH Terms]) AND dental implants[MeSH Terms] 
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Furthermore, the following search strategy was applied to Scopus and Web of Sciences to 
supplement records identified through Ovid and PubMed: 
(non steroidal anti inflammatory agent OR non steroidal anti inflammatory agents OR non steroidal 
anti inflammatory drug OR non steroidal anti inflammatory drugs OR cyclooxygenase inhibition OR 
COX inhibition OR ibuprofen OR celecoxib) AND (osseointegration OR osteoblast OR osteoblasts OR 
titanium implant OR titanium implants OR dental implant OR dental implants) 
Study Selection 
The titles and abstracts of each research article in the initial search were independently screened by 
the primary (JDL) and the second reviewer (TJ). A third independent reviewer (MN) reviewed the 
articles that were included by one but excluded by the other reviewer. The full-text manuscripts of 
the articles were catalogued in accordance to the Eligibility Criteria as mentioned above and were 
assessed for the following criteria:  
• the study explored the COX-pathway and its role in osseointegration, 
• the effects of NSAIDs on osteoblasts attached to titanium are investigated (in-vitro studies). 
Data Collection Process 
The full-text manuscripts of included studies were catalogued into in-vitro, clinical and in-vivo 
studies. The data from the included studies were independently extracted by the primary (JDL) and 
the second reviewer (TJ) according to the Data Items as listed below. Disagreements or uncertainties 
were discussed with the third reviewer (MN) until an agreement was reached. 
Data Items 
The data collected from the included studies were arranged in the following fields:  
• Author (Year) – reveals the author/s and year of publication. 
• Sample (Size) – describes the sample and sample size used in the study. 
• Treatment Group (Size) – describes the treatments used in study. 
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• Methodology – describes the method of drug delivery 
• Parameter – describes the parameter/s that are measured. 
• Outcome – describes the outcome/s of the experiments.  
Quality and Risk of Bias in Individual Studies 
The quality and risk of bias assessments were performed independently by two reviewers (JDL and 
TJ) during the data extraction process. Any disagreements or uncertainties were discussed with the 
third reviewer (MN) until an agreement was reached. The quality and bias assessment for all studies 
addressed various bias domains. A Modified CONSORT checklist of items for reporting in vitro 
studies of dental materials outlined by Faggion (Table 1-2) was used to assess quality and risk of bias 
of included in-vitro studies {Faggion, 2012 #528}. The Cochrane Collaboration’s Tool (Table 3) was 
used to assess quality and risk of bias of included human clinical studies {Higgins, 2011 #515}. A 
quality assessment of the methodology of the animal studies (Table 4) has been performed 
according to items (Table 5) of the ARRIVE guidelines {Kilkenny, 2010 #521}. 
 
Table 1.  Quality assessment of in-vitro studies according to the items of the Modified CONSORT checklist {Faggion, 2012 #528}. 
Study 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Summary 
Assessment 
Arpornmaeklong 
et al. 
{Arpornmaeklong, 
2008 #13} 
+ ? + + - - - - n/a + + - + - High 
Boyan et al. 
{Boyan, 2001 
#131} 
+ + + + - - - - n/a + + - + - High 
Key: (+)=low risk of bias, (?)=unclear risk of bias, (-)=high risk of bias 
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Table 5. Items of the ARRIVE Guidelines {Kilkenny, 2010 #521} 
Table 2. Modified CONSORT checklist of items for reporting in vitro studies of dental materials {Faggion, 2012 
#528} 
Item Domain 
1 Abstract: Structured summary of trial design, methods, results, and conclusions 
Introduction 
2 Scientific background and explanation of rationale with specific objectives and/or hypotheses 
Methods 
3 Intervention: The intervention for each group, including how and when it was administered, with 
sufficient detail to enable replication 
4 Outcomes: Completely defined, pre-specified primary and secondary measures of outcome, including 
how and when they were assessed 
5 Sample Size: How sample size was determined 
6 Randomisation: Method used to generate the random allocation sequence 
7 Allocation: Mechanism used to implement the random allocation sequence, describing any steps taken to 
conceal the sequence until intervention was assigned 
8 Implementation: Who generated the random allocation sequence, who enrolled teeth, 
and who assigned teeth to intervention 
9 Blinding: If done, who was blinded after assignment to intervention and how 
10 Statistics: Statistical methods used to compare groups for primary and secondary outcomes 
Results 
11 For each primary and secondary outcome, results for each group, and the estimated size of the effect and 
its precision 
Discussion 
12 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses 
Other information 
13 Sources of funding and other support role of funders 
14 Where the full trial protocol can be accessed, if available 
Table 3. Quality and Bias assessment of human clinical studies using The Cochrane Collaboration’s Tool {Higgins, 2011 #515}. 
Study Random 
Sequence 
Generation 
Allocation 
Concealment 
Blinding of 
Participants 
/ Personnel 
Blinding of 
Outcome 
Assessment 
Incomplete 
Outcome 
Data 
Selective 
Reporting 
Summary 
Assessment 
Alissa et al. {Alissa, 2009 #16} + + + ? + + Unclear 
Sakka et al. {Sakka, 2013 #9} - - - + + + High 
Winnett et al. {Winnett, 2016 
#30} 
n/a - - - ? + High 
Key: (+)=low risk of bias, (?)=unclear risk of bias, (-)=high risk of bias 
Table 4. Quality assessment of the methodology of the animal studies according to the items of the ARRIVE guidelines 
{Kilkenny, 2010 #521}.  
Study 5 6 7 8 9 10 11 12 13 Summary 
Assessment 
Cai et al. {Cai, 2015 
#436} 
+ ? + + ? ? ? + + Unclear 
Chikazu et al. 
{Chikazu, 2007 #423} 
+ - + + - - ? + + High 
Goodman et al. 
{Goodman, 2002 
#523} 
? + + + - ? - + + High 
Goodman et al. 
{Goodman, 2005 
#524} 
? + + + - ? - + + High 
Pablos et al. {Pablos, 
2008 #31} 
+ ? + + - - ? + + High 
Ribeiro et al. 
{Ribeiro, 2006 #21} 
+ ? + + - - ? + + High 
Ribeiro et al. 
{Ribeiro, 2009 #367} 
+ ? + + - - ? + + High 
Salduz et al. {Salduz, 
2017 #508} 
- + + + ? - + + + High 
Key: (+)=low risk of bias, (?)=unclear risk of bias, (-)=high risk of bias 
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Item Domain 
5 Ethical Statement 
6 Study Design 
7 Experimental Procedures 
8 Experimental Animals 
9 Housing and Husbandry 
10 Sample Size 
11 Allocating Animals to Experimental Groups 
12 Experimental Outcomes 
13 Statistical Analysis 
 
Synthesis of Results 
The relevant data collected for qualitative synthesis are summarised in three Critical Analysis Tables: 
in-vitro studies (Table 6), clinical studies (Table 7) and in-vivo studies (Table 8). 
Statistical Analysis 
No meta-analyses could be performed due to the heterogeneity between the studies – different 
samples, experimental groups (drugs and concentrations), study models and outcome measures. 
 
Results 
Study Selection 
The electronic search in the databases of Web of Science, PubMed, Ovid, and Scopus resulted in the 
identification of 875 potential titles and abstracts. After removal of the duplicates, independent 
screening of the abstracts resulted in the selection of 79 studies for assessment of eligibility. A total 
of 13 studies were eligible and are included in the systematic review (Figure 1). 
Exclusion of Studies 
The Eligibility and Study Selection criteria as mentioned above were applied to the 79 full-text 
articles. A total of 66 studies were excluded after full-text assessment for the following reasons: 
• the study did not explore the role of COX-pathway in osseointegration (n= 26) 
• the effects of NSAIDs on osteoblasts were not investigated on titanium (n= 24) 
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• the study was a systematic review (n= 16) 
Study Characteristics 
The included studies were catalogued into three groups characterised by the type of study: in-vitro 
studies (Table 6), clinical studies (Table 7) and in-vivo studies (Table 8). The cataloguing provided a 
clearer understanding of the effects of NSAIDs in osseointegration in various study models, 
ultimately contributing to the sensitivity of the systematic review. 
Quality and Risk of Bias Assessment 
The quality and risk of bias assessments of included studies are summarised in Tables 1-5. The 
quality assessment revealed a high-risk of bias (for one or more domain) for most of the included 
studies. The included in-vitro studies had high risk of bias according to the Modified CONSORT 
checklist {Arpornmaeklong, 2008 #13;Boyan, 2001 #131;Faggion, 2012 #528}. One clinical study was 
classified as unclear risk of bias (for one or more domain) according to the Cochrane Collaboration’s 
Tool {Alissa, 2009 #16;Higgins, 2011 #515}. An in-vivo animal study had an unclear risk of bias 
according to the ARRIVE guidelines {Kilkenny, 2010 #521;Cai, 2015 #436}. 
Discussion 
Non-steroidal anti-inflammatory drugs are widely used in clinical dentistry to manage post-operative 
inflammation and pain. Two systematic reviews have been performed to review the literature 
concerning the possible influence of NSAIDs on the osseointegration of titanium implants: a review 
conducted by Gomes et al. concluded that osseointegration is impaired in the presence of 
conventional NSAIDs; while the review conducted by Kalyvas et al. concluded that short-term post-
operative NSAIDs do not appear to negatively impact osseointegration {Kalyvas, 2008 #417;Gomes, 
2015 #500}. Despite these conflicting conclusions regarding post-operative use of NSAIDs, both 
Gomes et al. and Kalyvas et al. agreed that prolonged or long-term use of NSAIDs, particularly in 
patients with chronic diseases, impaired osseointegration and, therefore, reduced the success of 
implant surgery {Gomes, 2015 #500;Kalyvas, 2008 #417}. The current review extends on these 
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existing reviews by identifying if dosage, duration of administration, and selectivity of post-operative 
NSAIDs impair osseointegration.  
In-vitro Studies 
The effects of NSAIDs on the osteogenic activity of osteoblasts have been extensively studied at the 
molecular-pharmacological level {García-Martínez, 2015 #765}. However, only two studies have 
been identified that investigated the effect of NSAIDs on osteoblasts attached to titanium surfaces 
(Table 6). In the study conducted by Boyan et al., their results demonstrated that a non-selective 
COX-inhibitor (indomethacin, 0.1 µM), a selective COX-1 inhibitor (resveratrol, 1 and 10 µM), and a 
selective COX-2 inhibitor (NS-398, 1 and 10 µM) did not have a significant effect on the number of 
cells derived from human osteosarcomas {Boyan, 2001 #131}. Furthermore, Boyan et al. 
demonstrated that the NSAIDs reduced prostaglandin E2 (PGE2) production of cells attached to a 
rough titanium surface. Their results indicated that both COX-1 and COX-2 are involved in the 
production of osteocalcin, PGE2, and TGF-β1 by osteoblasts {Boyan, 2001 #131}. They also 
demonstrated that osteoblasts produced increased levels of PGE2 on rough titanium surfaces and 
that this was correlated with increased alkaline phosphatase activity and osteocalcin production 
{Boyan, 2001 #131}. This suggests that PGE2 may have a role in osteoblast proliferation and 
differentiation on titanium surfaces, and that this favourable effect of PGE2 was inhibited when a 
NSAID was present {Boyan, 2001 #131}. Arpommaeklong et al. found that a non-selective COX-
inhibitor (indomethacin, 0.1 µM) and a selective COX-2 inhibitor (celecoxib, 1.5, 3.0, and 9.0 µM) 
inhibited the growth of cell cultures derived from rat calvarias, where the effect was dose-
dependent in the cultures treated with celecoxib {Arpornmaeklong, 2008 #13}. Furthermore, 
Arpommaeklong et al. demonstrated that PGE2 levels were significantly lower in the groups that 
were treated with a NSAID, and have postulated that PGE2, consistent with Boyan et al., may have a 
role in osteoblast growth and differentiation {Arpornmaeklong, 2008 #13;Boyan, 2001 #131}. 
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Clinical Studies 
The clinical evidence demonstrating the effects of NSAIDs on the osseointegration of titanium dental 
implants is limited with only two clinical trials and one retrospective study identified in the database 
searches (Table 7). In the clinical trial conducted by Alissa et al., the effect of a 7-day post-operative 
course of ibuprofen (600 mg, taken 4-times daily) on the marginal bone level around dental implants 
was investigated {Alissa, 2009 #16}. They found that there were no statistically significant 
differences between the treated and placebo groups in the mean marginal bone level around dental 
implants at 3 and 6-months after implant placement {Alissa, 2009 #16}. In a similar clinical trial, 
conducted by Sakka et al. the effect of a 7-day course of ibuprofen (600 mg, taken 4-times daily) on 
the marginal bone level around dental implants was also investigated {Sakka, 2013 #9}. They found 
that there were no significant differences between the ibuprofen and non-ibuprofen groups, 
consistent with the findings of Alissa et al., when comparing the changes in marginal bone level 
around dental implants {Sakka, 2013 #9}. However, a retrospective study conducted by Winnett et 
al. postulated that the adverse biological events following dental implant placement were associated 
with peri-operative use of NSAIDs {Winnett, 2016 #30}. Winnett et al. reported a total loss of 197 
dental implants due to failed osseointegration from patients with failing implant/s (468 implants in 
104 patients) treated in a postgraduate dental clinic (between 1979-2012). The patients (n=60) that 
used NSAIDs peri-operatively experienced a total of 119 failed implants, whilst the non-NSAID cohort 
(n=44) experienced a total of 78 failed implants. Winnett et al. identified that ibuprofen (600 mg, 
taken 4-times daily) was the most commonly prescribed, however other prescribed NSAIDs included 
Ketorolac, Vioxx, Celebrex, Diflunisal, Meloxicam, and Naproxen {Winnett, 2016 #30}. Despite the 
clinical trials conducted by Alissa et al. and Sakka et al. both of whom have demonstrated that a 7-
day post-operative course of ibuprofen (600 mg, taken 4-times daily) did not significantly affect bone 
levels around dental implants at 3 and 6-month after placement, the data gathered by Winnett et al. 
indicates that NSAIDs may have detrimental effect on osseointegration {Winnett, 2016 #30}. 
Animal Studies 
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The influence of NSAIDS on bone-healing in animal models has been shown to be related to the 
duration of treatment and drug selectivity {Pountos, 2012 #313}. A total of 7 studies were identified 
that investigated the effect of NSAIDs on the osseointegration of titanium implants in animals: mice, 
rabbits and rats (Table 8).  
The duration of treatment is a factor to consider when using NSAIDs, and a study conducted by 
Goodman et al., investigated the effect of a selective COX-2 inhibitor (rofecoxib, 12.5mg/kg/day) 
administered for 6-weeks on bone growth in a bone-harvest chamber during 3 different time 
periods: initial 2 of the 6-weeks, final 2 of the 6-weeks, and continuously for 6-weeks {Goodman, 
2005 #524}. The bone harvest chamber was a titanium device that was implanted into the tibia of 
rabbits and had an inner removable core with canals that allowed for bone ingrowth into the inner 
chamber. Their results revealed that rofecoxib given continuously for 6-weeks significantly reduced 
bone ingrowth, and osteoblasts per area compared with the control (no treatment), whilst rofecoxib 
given for 2-weeks did not appear to interfere with bone ingrowth, and number of osteoblasts 
{Goodman, 2005 #524}. Furthermore, in studies conducted by Ribeiro et al. they investigated the 
effect of long-term administration (60-days) of a selective COX-2 inhibitor (meloxicam, 3mg/kg/day) 
on the bone growth on a titanium implant {Ribeiro, 2006 #21;Ribeiro, 2009 #367}. Their results also 
indicated that long-term use of a selective COX-2 NSAID significantly reduces bone-to-implant 
contact, bone area, and bone density, ultimately leading to failed osseointegration {Ribeiro, 2006 
#21}. The data gathered in both studies suggest that duration of treatment is an important factor in 
the use of selective COX-2 NSAIDs, as short-periods of rofecoxib and meloxicam did not adversely 
affect osseointegration {Goodman, 2005 #524;Ribeiro, 2006 #21}.  
The COX-selectivity of NSAIDs and their interference with prostaglandin synthesis have been shown 
to inhibit bone-healing {García-Martínez, 2015 #765}. Goodman et al. performed a follow-up study 
where the titanium bone harvest chamber was implanted again into the tibia of rabbits and the 
rabbits were treated with water (control), a non-selective COX-inhibitor (naproxen, 110mg/kg/day), 
or a selective COX-2 inhibitor (rofecoxib, 12.5mg/kg/day) for a 4-week period {Goodman, 2002 
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#523}. Their results again demonstrated that COX-2 inhibition significantly decreased bone-ingrowth, 
where rofecoxib also decreased the number of osteoblasts per area {Goodman, 2002 #523}. 
Furthermore, the conclusions by Goodman et al. were supported by the study by Chikazu et al. 
where titanium implants were inserted in wild-type and COX-2 knockout mice {Chikazu, 2007 #423}. 
Their results revealed that the expression of COX-2 was induced in bone surrounding the implants in 
wild-type mice, but not in COX-2 knockout mice and that the bone-to-implant contact was minimal 
in newly formed bone in COX-2 knockout mice {Chikazu, 2007 #423}. The data collected by Goodman 
et al. and Chikazu et al. postulated that COX-2 may have an important role in osseointegration 
{Chikazu, 2007 #423;Goodman, 2005 #524}. However, in study conducted by Pablos et al., that 
investigated the effect of a non-selective COX-inhibitor (diclofenac, 1.07mg/kg/day) and a selective 
COX-2 inhibitor (meloxicam, 0.2mg/kg/day) administered for 5-days on peri-implant healing in rats 
revealed diclofenac delayed peri-implant bone healing and negatively affected the bone-to-implant 
contact, whereas meloxicam had no negative effect on peri-implant healing {Pablos, 2008 #31}. The 
results of Pablos et al. were inconsistent with the results of the study conducted by Cai et al. that 
also investigated the effect of diclofenac (2mg/kg/day) and a selective COX-2 inhibitor (parecoxib, 
1.5mg/kg/day) administered for 7-days on the osseointegration of titanium implants in rabbit 
calvarias. Their results revealed no statistically significant differences between the experimental 
groups and the control {Cai, 2015 #436}. Furthermore, in a recent study conducted by Salduz et al. 
that investigated the effect of a non-selective COX-inhibitor (diclofenac, 5mg/kg/day) and a selective 
COX-2 inhibitor (celecoxib, 3mg/kg/day) administered for 8-weeks on bone growth and 
osseointegration on two different alternative titanium surfaces, revealed no statistically significant 
differences in the biomechanical and histological results between the experimental groups and the 
control, suggesting that long-term use of NSAIDs does not affect osseointegration {Salduz, 2017 
#508}. The data collected in animal studies regarding duration of treatment and drug selectivity is 
inconsistent, and there is a lack of consensus on the influence of NSAIDs on osseointegration in 
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animal models. 
 
Limitations 
The majority of the included studies revealed a high risk of bias and conclusions from studies that 
have a high risk of bias is sufficient to affect interpretation of data {Higgins, 2011 #515;Kilkenny, 
2010 #521;Faggion, 2012 #528}. Publication and selection bias is apparent in several included 
studies, as the negative effects of NSAIDs on osseointegration can be expected in the studies that 
administered NSAID at a high concentration and/or for a prolonged period of time. The conclusions 
of this systematic review were largely based on animal studies, as there are very few published in-
vitro and clinical studies relating to the effect of NSAIDs on osseointegration. The effects of NSAIDs 
on osseointegration in animals cannot be translated to humans due to the vastly different 
pharmacokinetics. 
 
Conclusions 
The analgesic and therapeutic effects of NSAIDs are achieved by COX-2 inhibition {Gomes, 2015 
#500}. It is likely that COX-inhibition by NSAIDs is detrimental to the bone healing process, given the 
favourable actions of PG on this process {Gomes, 2015 #500}. Osteoblasts have the capacity to 
produce PGs, where PGE2 is most abundant, through the COX pathway though the evidence 
asserting that PGs have a direct role in bone healing is inconclusive {García-Martínez, 2015 
#765;Salari, 2009 #193}. Furthermore, there is insufficient evidence in the current literature to 
explicitly conclude that there is a relationship between the use of NSAIDs and early implant failure. 
However, osseointegration does not appear to be negatively affected by NSAIDs in the human 
clinical studies, which contrasts with the experimental in-vitro and in-vivo animal studies. 
Furthermore, there are no human clinical studies that have investigated the effect of a selective 
COX-2 NSAID on osseointegration. Therefore, further research with an emphasis in human clinical 
studies comparing the effect of the COX-selectivity of NSAIDs on osseointegration is required. 
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Tables 6-8 – Materials and Methods: Synthesis of Results (cite) 
Table 6. In-vitro studies that investigated the effect of NSAIDs on osteoblasts attached to titanium surfaces 
Study (Year) Sample Treatment Group Methodology Parameter Outcome 
Arpornmaeklong 
et al.  
(2009) 
{Arpornmaeklong, 
2008 #13} 
 
Mouse calvaria cell 
line (MC3T3-E1) 
Indomethacin 0.1 μM 
Celecoxib 1.5 μM 
Celecoxib 3.0 μM 
Celecoxib 9.0 μM 
Control 
Incubation in treatment 
medium for 5 days. 
Investigations were 
performed in 3 
experimental phases: 
static, log, plateau 
 
The following 
parameters were 
assessed at 1, 3 and 5-
days: Cell Attachment, 
Cell Growth, Cell 
differentiation, 
Secretion of PGE2 
Cells were able to grow and attach to 
titanium surface for all treatment 
groups. 
Indomethacin and celecoxib cell growth 
on days 3 and 5 in static phase and on 
day 3 in log phase. 
Indomethacin and celecoxib caused a 
significant decrease PGE2 concentration 
in static and plateau but not log phases. 
Boyan et al. 
(2001) {Boyan, 
2001 #131} 
Human 
osteosarcoma cell 
line (MG63) 
Indomethacin 0.1 μM 
Resveratrol 1 μM 
Resveratrol 10 μM 
NS-398 1 μM 
NS-398 10 μM 
Incubation in treatment 
medium for 5 days. 
Cells were cultured on: 
tissue culture plastic, 
smooth titanium, two 
rough titanium surfaces: 
grit-blasted/acid-etched 
and titanium-plasma 
sprayed 
 
The following 
parameters were 
assessed after 5-days: 
Osteocalcin content,  
PGE2 content,  
TGF-β1 content. 
Indomethacin, resveratrol, and NS-398 
had no effect on osteocalcin content. 
Indomethacin and resveratrol blocked 
PGE2 production. NS-398 had no effect 
on PGE2 production on smooth 
surfaces but caused a reduction on 
rough surfaces. 
Indomethacin blocked TGF-β1 
production on rough surfaces. 
Resveratrol blocked TGF-β1 on TPS. NS-
398 did not cause TGF-β1 inhibition. 
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Table 7. Clinical studies that investigated the effect of NSAIDs on osseointegration 
Study (Year) Sample (Size) Treatment Group (Size) Methodology Parameter Outcome 
Alissa et al.  
(2009) {Alissa, 
2009 #16} 
Eligible human 
patients (n= 61). 
Implants inserted  
(n= 132). 
Ibuprofen (n= 31),  
Implants (n= 67). 
Placebo (n=30),  
Implants (n= 65). 
Ibuprofen, 600mg q.i.d. for 7-
days orally 
Post-operative 
radiographic marginal-
bone height at 3 and 
6-months 
No statistically significant 
differences in mean marginal 
bone level changes at 3 or 6-
months. 
Sakka et al. 
(2013) {Sakka, 
2013 #9} 
Eligible human 
patients (n= 28). 
Implants inserted  
(n= 57). 
Ibuprofen (n= 14),  
Implants (n=31). 
Non-Ibuprofen (n= 14), 
Implants (n= 26). 
Ibuprofen, 600mg q.i.d. for 7-
days orally 
 
Post-operative 
radiographic marginal-
bone height at 3 and 
6-months 
No statistically significant 
differences in mean marginal 
bone level changes at 3 or 6-
months. 
Winnett et al. 
(2014) 
{Winnett, 2016 
#30} 
Patients treated 
between 1979-2012 
with failed and 
surgically removed 
dental implants 
Cohort that used post-
operative NSAIDs  
(n= 60, with 119 failed 
implants). 
Cohort that did not use 
post-operative NSAIDs  
(n= 44, with 78 failed 
implants). 
Ibuprofen was the most 
commonly prescribed, 600mg 
q.i.d.  
Other prescribed analgesics 
were: Ketorolac, Vioxx, 
Celebrex, Diflunisal, 
Meloxicam, Paracetamol, and 
Naproxen. 
Radiographic bone 
loss. 
Vertical bone height of 
remaining implants. 
NSAID cohort experienced more 
implant failures than the non-
NSAID cohort. 
The NSAID cohort experienced 
more cases of radiographic 
bone loss greater than 30% of 
the vertical height of their 
remaining implants. 
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Table 8. In-vivo studies using animal-models that investigated the effect of NSAIDs on osseointegration 
Study (Year) Sample (Size) Treatment Group (Size) Methodology Parameter Outcome 
Cai et al.  
(2015) {Cai, 2015 
#436} 
New Zealand white 
rabbits (n=18). 
Implant inserted into 
calvaria (n=18). 
Control (n= 6) 
Diclofenac (n= 6) 
Parecoxib (n= 6) 
Treatments were 
administered for 7-days:  
Diclofenac, 2mg/kg/day 
orally 
Parecoxib, 1.5mg/kg/day 
subcutaneous injection 
Parameters observed at week 4 
and 12 after implantation:  
Micro-CT: bone-volume ratio, 
mean trabecular thickness, and 
mean trabecular separation. 
Histomorphometric: bone-to-
implant contact. 
No statistically significant 
differences between the 
three separate groups, nor 
between the different time 
points. 
Chikazu et al.  
(2007) {Chikazu, 
2007 #423} 
9-week old male 
mice (n= 72). 
Implant inserted in 
femur (n= 72). 
Mice with the 
original C57BL6/129S7 
hybrid background were 
generated and 
maintained:  
Wild-type (n= 36)  
COX-2 knockout (n= 36) 
 
No drug was administered mRNA levels were observed at 
days 0, 1, 2, 4 ,7 and 56 after 
implant insertion: expression of 
COX-2 and osteocalcin mRNA. 
Histomorphometric analysis at 
week 4 and 8: bone-to-implant 
contact. 
 
Expression of COX-2 and 
osteocalcin mRNA was 
induced in bone surrounding 
implants in wild-type mice, 
but not in knockout mice. 
Bone-to-implant contact was 
minimal in knockout mice. 
Goodman et al. 
(2002) {Goodman, 
2002 #523} 
New Zealand white 
rabbits (n= 8). 
Titanium bone 
harvest chamber 
inserted in tibia  
(n= 8).  
Control 
Naproxen 
Rofecoxib 
Treatments administered:  
Control: week 0-4 and 9-
12. 
Naproxen, 110mg/kg: 
week 5-8 orally. 
Rofecoxib, 12.5mg/kg: 
week 13-16 orally. 
Immunohistochemistry 
observed: total tissue area, 
total bone area, ratio of bone 
area, and total number of 
osteoblasts and osteoclast-like 
cells per section area 
 
Naproxen and rofecoxib 
decreased bone ingrowth 
significantly.  
Rofecoxib decreased the 
area of osteoblasts per area 
compared with controls, and 
naproxen sodium did not 
reach statistical significance. 
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Table 8. (continued)  
Study (Year) Sample (Size) Treatment Group (Size) Methodology Parameter Outcome 
Goodman et al. 
(2005) {Goodman, 
2005 #524} 
New Zealand white 
rabbits (n= 8). 
Titanium bone 
harvest chamber 
implanted bilaterally 
in tibia (n= 16). 
Control 
Rofecoxib  
Treatments were 
administered for 6-weeks 
each:  
control-no drug;  
rofecoxib (12.5 mg/day) 
for the first 2 weeks of a 
6-week trial, or the last 2 
weeks or given 
continuously for all 6 
weeks washout periods 
Immunohistochemistry 
observed: total tissue area, 
total bone area, ratio of bone 
area, and the total number of 
osteoblasts and osteoclast-like 
cells per section area. 
Rofecoxib given 
continuously for 6 weeks 
had less bone ingrowth, 
osteoclast-like cells and 
osteoblasts per area 
compared to the control 
treatment. 
Rofecoxib given for 2 of a 6-
weeks cycle did not interfere 
with the parameters. 
Pablos et al.  
(2008) {Pablos, 
2008 #31} 
Male Sprague-
Dawley rats, 3-
months old, 
weighing 250-300g 
(n= 30). 
Implant inserted in 
tibia (n=30). 
Control (n= 10) 
Diclofenac (n= 10) 
Meloxicam (n= 10) 
Diclofenac, 1.07 mg/kg 
b.i.d. for 5-days. 
Meloxicam, 0.2mg/kg 
daily for 5-days. 
Histomorphometric analysis at 
28-days after implant insertion: 
bone-to-implant contact, 
cortical bone area, and 
trabecular bone area within the 
implant threads 
The bone-to-implant contact 
was lower in diclofenac 
compared with the 
meloxicam and control. 
The trabecular bone area 
was greater in diclofenac 
compared with meloxicam 
and control. 
Ribeiro et al. 
(2006) {Ribeiro, 
2006 #21} 
Male Wistar rats, 
aged 10 weeks  
(n= 31). 
Implant inserted in 
tibia (n=31). 
Control (n= 14) 
Meloxicam (n = 17) 
Daily subcutaneous 
injections for 60-days:  
Control, 1mL/kg of saline  
Meloxicam, 3mg/kg 
Histomorphometric analysis at 
60-days after implant insertion: 
bone-to-implant contact, bone 
area, and bone density in the 
cortical and cancellous bone 
areas 
Meloxicam reduced bone-
to-implant contact, bone 
area, and bone density in 
both the cortical and 
cancellous bone areas. 
Ribeiro et al. 
(2009) {Ribeiro, 
2009 #367} 
Male Wistar rats, 
aged 10 weeks  
(n= 30). 
Implant inserted in 
tibia (n=30). 
Control (n= 14) 
Meloxicam (n = 16) 
Daily subcutaneous 
injections for 60-days:  
Control, 1mL/kg of saline  
Meloxicam, 3mg/kg 
Histomorphometric analysis at 
60-days after implant insertion: 
bone-to-implant contact, bone 
area, and bone density in the 
cortical and cancellous bone 
areas 
Blasting implant surface with 
aluminium oxide can 
increase bone-to-implant 
contact, however, it does 
not reverse the negative 
effects caused by a selective 
COX-2 inhibitor on bone 
healing around implants. 
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Table 8. (continued)  
Study (Year) Sample (Size) Treatment Group (Size) Methodology Parameter Outcome 
Salduz et al. 
(2017) {Salduz, 
2017 #508} 
New Zealand white 
rabbits, skeletally 
mature weighing 
3.5-4kg (n=40). 
Titanium rods 
implanted bilaterally 
in femur (n= 80). 
Control 
Diclofenac 
Celecoxib 
Treatments were 
administered for 8-
weeks: 
Control, regular food 
Diclofenac, 5mg/kg/day 
intramuscularly 
Celecoxib, 3mg/kg/day 
orally 
Biomechanical and 
histomorphometric analysis at 8-
weeks after implant insertion: 
interface failure load, bone 
quality, bone–implant interface, 
host reaction, total bone area, 
bone-to-implant contact rate 
No significant difference in 
the biomechanical and 
histological results 
between the groups. 
 
 
 
 
